Global Information
회사소개 | 문의 | 위시리스트

미국의 건선용 생물제제 및 바이오시밀러 치료제 시장

The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis

리서치사 MP Advisors
발행일 2017년 10월 상품 코드 565345
페이지 정보 영문 104 Pages
가격
US $ 4,000 ₩ 4,735,000 PDF by E-mail (Single User License)
US $ 8,000 ₩ 9,470,000 PDF by E-mail (Three User License)
US $ 12,000 ₩ 14,205,000 PDF by E-mail (5 User License)
US $ 12,000 ₩ 14,205,000 PDF by E-mail (Enterprise User License)


미국의 건선용 생물제제 및 바이오시밀러 치료제 시장 The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis
발행일 : 2017년 10월 페이지 정보 : 영문 104 Pages

미국의 건선용 생물제제 및 바이오시밀러 치료제 시장에 대해 조사 분석했으며, 생물제제 치료제 주요 출시 제품, 파이프라인 제품, 성장에 영향을 미치는 요인, 경쟁 구도, 바이오시밀러 인가 완료 제품, 임상시험 중인 제품, 성장에 영향을 미치는 요인, 경쟁 구도 등의 정보를 전해드립니다.

제1장 건선 시장 개요

제2장 건선 생물제제 치료제 시장

  • 서론 및 시장 개요
  • 미국의 생물제제 매출 분석
  • 건선 치료제 주요 출시 제품
    • Remicade(infliximab; Janssen)
    • Humira(adalimumab; AbbVie)
    • Stelara(ustekinumab; Janssen)
    • Cosentyx(secukinumab; Novartis)
    • Taltz(ixekizumab; Lilly)
    • Siliq(brodalumab; Valeant)
    • Tremfya(guselkumab; Janssen)
  • 건선 치료제 주요 파이프라인 제품
    • Tildrakizumab; Merck / Sun Pharma
    • Cimzia(certolizumab pegol; UCB/Dermira Pharmaceuticals)
    • Risankizumab; AbbVie/Boehringer Ingelheim
  • 생물제제 성장 촉진요인 및 억제요인
  • 경쟁 구도 : 인가 제품
  • 경쟁 구도 : 파이프라인 제품

제3장 건선 바이오시밀러 시장

  • 서론 및 시장 개요
  • 인가 완료 바이오시밀러
    • 미국의 인가 완료 바이오시밀러
    • 미국의 바이오시밀러 매출 분석
    • EU의 인가 완료 바이오시밀러
  • 파이프라인 분석
    • 임상시험 : Humira(adalimumab) 바이오시밀러
    • 임상시험 : Enbrel(etanercept) 바이오시밀러
    • 임상시험 : Remicade(infliximab) 바이오시밀러
  • 바이오시밀러 계약과 제휴
  • 바이오시밀러 성장 촉진요인 및 억제요인
  • 경쟁 구도 : 미국 및 EU의 인가 완료 바이오시밀러
  • 경쟁 구도 : TNF 알파 저해 바이오시밀러 파이프라인

참고자료

LSH 17.10.31

The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to reach $12.9bn in 2021 driven by safety and efficacy improvements of the new generation biologics.

The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents. The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents.

Driven by improved efficacy, the first group of anti TNF treatments led by Enbrel, Humira and Remicade made strong penetration into the psoriasis market. However the emergence of the IL-17 inhibitor class driven by Novartis' Cosentyx and Eli Lilly's Talz have set a new benchmark for efficacy in moderate to severe psoriasis treatment with potential for safety improvement in comparison to the anti TNF drugs given their greater specificity in immune Suppression. MP Advisors expect the TNF class of drugs to lose share to the newer brands with improved clinical profiles in Psoriasis.

The market growth in psoriasis is driven by an upsurge in demand from new therapies in moderate to severe patient population which overshadows reduced pricing of branded TNF-α inhibitor and recent biosimilar launches. The psoriasis treatment market is facing increasing competitive pressure from a wave of biosimilar launches such as biosimilars of Janssen's Remicade, and Amgen's Enbrel with the impact of the headwinds expected to be more pronounced in the next few years.

Stelara has been an important growth driver of Janssen's immunology franchise in recent years, with overall global sales doubling from $1.5bn in 2013 to more than $3.2bn in 2016. However Stelara has started to face steeper competition from the IL-17 drug class. A new head-to-head study report IL-17 products to demonstrate superior efficacy to Stelara for psoriasis.

Table of Contents

Executive Summary

List of Figures

List of Tables

1. Psoriasis Market Overview

  • 1.1. Disease background
  • 1.2. Types of psoriasis
    • 1.2.1. Plaque psoriasis
    • 1.2.2. Guttate psoriasis
    • 1.2.3. Inverse (flexural) psoriasis
    • 1.2.4. Pustular psoriasis
    • 1.2.5. Erythrodermic psoriasis
  • 1.3. Pathophysiology
  • 1.4. Etiology
    • 1.4.1. Environmental factors
    • 1.4.2. Genetic factors
    • 1.4.3. Immunologic factors
  • 1.5. Risk factors and co-morbidities
  • 1.6. Epidemiology
  • 1.7. Treatment options
    • 1.7.1. Phototherapy
    • 1.7.2. Topical treatments
    • 1.7.3. Conventional systemic agents
    • 1.7.4. Other systemic drugs
    • 1.7.5. Biologics
  • 1.8. Treatment Guidelines
    • 1.8.1. Mild to moderate Psoriasis
    • 1.8.2. Moderate Psoriasis
    • 1.8.3. Moderate -to-severe psoriasis
    • 1.8.4. Severe psoriasis

2. Psoriasis Treatment Market for Biologics

  • 2.1. Introduction and Market Overview
  • 2.2. Revenue Analysis for Biologics in the U.S.
  • 2.3. Key marketed products for psoriasis treatment
    • 2.3.1. Remicade (infliximab; Janssen)
    • 2.3.2. Humira (adalimumab; AbbVie)
    • 2.3.3. Stelara (ustekinumab; Janssen)
    • 2.3.4. Cosentyx (secukinumab; Novartis)
    • 2.3.5. Taltz (ixekizumab; Lilly)
    • 2.3.6. Siliq (brodalumab; Valeant)
    • 2.3.7. Tremfya (guselkumab; Janssen)
  • 2.4. Key pipeline products for psoriasis treatment
    • 2.4.1. Tildrakizumab; Merck / Sun Pharma
    • 2.4.2. Cimzia (certolizumab pegol; UCB/Dermira Pharmaceuticals)
    • 2.4.3. Risankizumab; AbbVie/Boehringer Ingelheim
  • 2.5. Growth Drivers and Resistors for Biologics
    • 2.5.1. Growth Drivers:
    • 2.5.2. Resistors
  • 2.6. Competitive Landscape - Approved Products
  • 2.7. Competitive Landscape - Pipeline Products

3. Psoriasis Market for Biosimilars

  • 3.1. Introduction and Market Overview
  • 3.2. Approved biosimilars
    • 3.2.1. Approved biosimilars in the U.S.
    • 3.2.2. Revenue Analysis for Biosimilars in U.S.
    • 3.2.3. Approved biosimilars in the EU
  • 3.3. Pipeline Analysis
    • 3.3.1. Clinical development - Humira (adalimumab) biosimilars
    • 3.3.2. Clinical development - Enbrel (etanercept) biosimilars
    • 3.3.3. Clinical development - Remicade (infliximab) biosimilars
  • 3.4. Biosimilars deals and partnerships
  • 3.5. Growth Drivers and Resistors for Biosimilars
    • 3.5.1. Growth Drivers
    • 3.5.2. Resistors
  • 3.6. Competitive Landscape - Approved Biosimilars in the U.S. and EU
  • 3.7. Competitive Landscape - TNF α Inhibitors Biosimilars Pipeline

References:

Back to Top
전화 문의
F A Q